1. Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study
- Author
-
Jessica Cusato, Davide Giuseppe Ribaldone, Michela Helga Falzone, Alessandra Manca, Miriam Antonucci, Alice Palermiti, Giorgio Maria Saracco, Linda Ceccarelli, Francesco Costa, Andrea Bottari, Ginevra Fornaroli, Gian Paolo Caviglia, Antonio D’Avolio, and Lorenzo Bertani
- Subjects
IBD ,TDM ,monoclonal antibody ,personalized therapy ,Biology (General) ,QH301-705.5 - Abstract
Over the years, vedolizumab (VDZ) has emerged as a more effective target therapy for inflammatory bowel disease. The aim of this work was to analyze a cohort of inflammatory bowel disease patients, evaluating the association between VDZ serum concentrations at 6 months from starting therapy and their clinical and biochemical indexes within one year of treatment, correlating drug levels with response and clinical remission. Forty patients treated with VDZ were enrolled. Drug concentrations were quantified through ELISA methods. VDZ levels correlated with hemoglobin levels at twelve months of therapy (p = 0.03) and with clinical remission at twelve months of therapy (p = 0.03); patients who reached clinical remission showed higher VDZ concentrations. A VDZ cut-off value of 43.1 μg/mL was suggested, predicting clinical remission at twelve months of therapy. A statistically significant association between VDZ levels at T6 and calprotectin p = 0.04). Furthermore, the optimal threshold value of VDZ levels at T6 associated with calprotectin
- Published
- 2024
- Full Text
- View/download PDF